~~<i id='C0D0D37307'><strike id='C0D0D37307'><tt id='C0D0D37307'><pre id='C0D0D37307'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：hotspot 2025-10-02 05:17:42 Page View：5264

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to protect patients from sexual assault
Next article： New air purifier tech could be key to improving indoor air quality

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Reframing the conversation around gain

DebatesoverCovid'soriginshavebroughtnewattentiontotherisksofgain-of-functionresearch,butnotthebenefi

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Biden White House, tech companies launch new safeguards around emerging AI technology

5:47PresidentJoeBidenspeaksaboutartificialintelligenceintheRooseveltRoomoftheWhiteHouse,July2,2023.M

WSS

knowledge

knowledge

comprehensive

explore

Biden White House, tech companies launch new safeguards around emerging AI technology